vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($263.6M vs $192.4M, roughly 1.4× Xometry, Inc.). BALCHEM CORP runs the higher net margin — 14.9% vs -4.5%, a 19.4% gap on every dollar of revenue. On growth, Xometry, Inc. posted the faster year-over-year revenue change (29.5% vs 9.8%). Over the past eight quarters, Xometry, Inc.'s revenue compounded faster (25.2% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
BCPC vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $192.4M |
| Net Profit | $39.2M | $-8.6M |
| Gross Margin | 35.6% | 39.1% |
| Operating Margin | 19.8% | -4.6% |
| Net Margin | 14.9% | -4.5% |
| Revenue YoY | 9.8% | 29.5% |
| Net Profit YoY | 16.8% | 12.7% |
| EPS (diluted) | $1.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $192.4M | ||
| Q3 25 | $267.6M | $180.7M | ||
| Q2 25 | $255.5M | $162.5M | ||
| Q1 25 | $250.5M | $151.0M | ||
| Q4 24 | $240.0M | $148.5M | ||
| Q3 24 | $239.9M | $141.7M | ||
| Q2 24 | $234.1M | $132.6M | ||
| Q1 24 | $239.7M | $122.7M |
| Q4 25 | $39.2M | $-8.6M | ||
| Q3 25 | $40.3M | $-11.6M | ||
| Q2 25 | $38.3M | $-26.4M | ||
| Q1 25 | $37.1M | $-15.1M | ||
| Q4 24 | $33.6M | $-9.9M | ||
| Q3 24 | $33.8M | $-10.2M | ||
| Q2 24 | $32.1M | $-13.7M | ||
| Q1 24 | $29.0M | $-16.6M |
| Q4 25 | 35.6% | 39.1% | ||
| Q3 25 | 35.7% | 39.9% | ||
| Q2 25 | 36.4% | 40.1% | ||
| Q1 25 | 35.2% | 37.3% | ||
| Q4 24 | 36.0% | 39.7% | ||
| Q3 24 | 35.6% | 39.4% | ||
| Q2 24 | 35.5% | 39.9% | ||
| Q1 24 | 34.0% | 39.0% |
| Q4 25 | 19.8% | -4.6% | ||
| Q3 25 | 20.4% | -6.1% | ||
| Q2 25 | 20.1% | -6.3% | ||
| Q1 25 | 20.4% | -10.2% | ||
| Q4 24 | 19.8% | -7.8% | ||
| Q3 24 | 20.0% | -8.1% | ||
| Q2 24 | 19.6% | -11.5% | ||
| Q1 24 | 17.4% | -14.6% |
| Q4 25 | 14.9% | -4.5% | ||
| Q3 25 | 15.1% | -6.4% | ||
| Q2 25 | 15.0% | -16.3% | ||
| Q1 25 | 14.8% | -10.0% | ||
| Q4 24 | 14.0% | -6.7% | ||
| Q3 24 | 14.1% | -7.2% | ||
| Q2 24 | 13.7% | -10.3% | ||
| Q1 24 | 12.1% | -13.5% |
| Q4 25 | $1.21 | — | ||
| Q3 25 | $1.24 | — | ||
| Q2 25 | $1.17 | — | ||
| Q1 25 | $1.13 | — | ||
| Q4 24 | $1.03 | — | ||
| Q3 24 | $1.03 | — | ||
| Q2 24 | $0.98 | — | ||
| Q1 24 | $0.89 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $275.6M |
| Total Assets | $1.7B | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $219.1M | ||
| Q3 25 | $65.1M | $224.5M | ||
| Q2 25 | $65.4M | $225.8M | ||
| Q1 25 | $49.9M | $231.4M | ||
| Q4 24 | $49.5M | $239.8M | ||
| Q3 24 | $73.7M | $234.0M | ||
| Q2 24 | $63.7M | $240.9M | ||
| Q1 24 | $60.3M | $253.8M |
| Q4 25 | $1.3B | $275.6M | ||
| Q3 25 | $1.3B | $272.0M | ||
| Q2 25 | $1.3B | $270.4M | ||
| Q1 25 | $1.2B | $309.9M | ||
| Q4 24 | $1.1B | $314.5M | ||
| Q3 24 | $1.2B | $315.2M | ||
| Q2 24 | $1.1B | $315.8M | ||
| Q1 24 | $1.1B | $320.4M |
| Q4 25 | $1.7B | $703.7M | ||
| Q3 25 | $1.7B | $698.9M | ||
| Q2 25 | $1.7B | $687.0M | ||
| Q1 25 | $1.6B | $690.1M | ||
| Q4 24 | $1.6B | $680.1M | ||
| Q3 24 | $1.6B | $678.2M | ||
| Q2 24 | $1.6B | $678.6M | ||
| Q1 24 | $1.6B | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $4.4M |
| Free Cash FlowOCF − Capex | — | $-5.9M |
| FCF MarginFCF / Revenue | — | -3.0% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $4.4M | ||
| Q3 25 | $65.6M | $5.8M | ||
| Q2 25 | $47.3M | $-427.0K | ||
| Q1 25 | $36.5M | $-3.7M | ||
| Q4 24 | $52.3M | $9.1M | ||
| Q3 24 | $51.3M | $-3.6M | ||
| Q2 24 | $45.0M | $-9.1M | ||
| Q1 24 | $33.4M | $-11.7M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-9.2M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $-8.4M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-16.1M |
| Q4 25 | — | -3.0% | ||
| Q3 25 | — | -0.9% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | -6.0% | ||
| Q2 24 | — | -10.2% | ||
| Q1 24 | — | -13.1% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 3.6% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | 1.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
